Dr. Rakesh C Arora, MD, PhD
Claim this profileSt. Boniface General Hospital
Studies Malnutrition
Studies Frailty Syndrome
2 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Rakesh C Arora, MD, PhD is currently running
Single vs Multiple Arterial Grafts
for Heart Disease
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups.
Recruiting1 award N/A4 criteria
Protein Supplement
for Frailty in Heart Surgery Patients
Heart disease in an aging population has resulted in heart surgery being offered to older and more frail patients. Frail patients which make up more than 50% of patients currently undergoing heart surgery are vulnerable to having long-recovery times after surgery, greater loss of independence (i.e. being admitted to a nursing home), experience more depression and anxiety, and have a worse quality of life. In fact, nearly 10% of frail, older adult patients die within 30 days after their heart surgery. The Investigators previous study found that weight-loss and poor muscle strength (i.e. weakness) of frail patients can lead to a worse recovery after heart surgery. Furthermore, inadequate nutrition (aka. malnutrition which is defined as an unintentional, nutritional intake imbalance (not necessarily a decreased intake) before an operation can lead to a vicious cycle of muscle loss causing more frailty, a desire to eat less leading to more muscle loss and increased frailty. At present there is no process to address this important issue in older adults undergoing heart surgery. The Investigators propose to study a practical, real-world, treatment plan that focuses on good nutrition to prevent muscle loss and reduced frailty in vulnerable heart surgery patients.
Recruiting0 awards N/A6 criteria
More about Rakesh C Arora, MD, PhD
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Rakesh C Arora, MD, PhD has experience with
- ISOlution Protein Supplement
- Placebo Supplement
- Multiple Arterial Grafting
- Single Arterial Graft
Breakdown of trials Rakesh C Arora, MD, PhD has run
Frailty Syndrome
Cardiovascular Disease
Coronary Artery Disease
Heart Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rakesh C Arora, MD, PhD specialize in?
Rakesh C Arora, MD, PhD focuses on Malnutrition and Frailty Syndrome. In particular, much of their work with Malnutrition has involved treating patients, or patients who are undergoing treatment.
Is Rakesh C Arora, MD, PhD currently recruiting for clinical trials?
Yes, Rakesh C Arora, MD, PhD is currently recruiting for 2 clinical trials in Winnipeg Manitoba. If you're interested in participating, you should apply.
Are there any treatments that Rakesh C Arora, MD, PhD has studied deeply?
Yes, Rakesh C Arora, MD, PhD has studied treatments such as ISOlution protein supplement, Placebo Supplement, Multiple arterial grafting.
What is the best way to schedule an appointment with Rakesh C Arora, MD, PhD?
Apply for one of the trials that Rakesh C Arora, MD, PhD is conducting.
What is the office address of Rakesh C Arora, MD, PhD?
The office of Rakesh C Arora, MD, PhD is located at: St. Boniface General Hospital, Winnipeg, Manitoba R2H2A6 Canada. This is the address for their practice at the St. Boniface General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.